Efficacy and safety of envafolimab plus lenvatinib combined with TACE in initially unresectable hepatocellular carcinoma: An open-label, single-arm, phase II study

被引：0
|
作者：
Bai, Xueli
Chen, Yiwen
Zhang, Junlei
Hu, Wendi
Li, Xiang
Shen, Yan
Zhang, Min
Wu, Jian
Gao, Shunliang
Yu, Jun
Que, Risheng
Zhang, Yun
Yang, Fuchun
Xia, Weiliang
Zhang, Aibin
Tang, Xiaofeng
Liang, Tingbo
机构：
[1] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Hangzhou, Peoples R China
[2] Zhejiang Univ, Affiliated Hosp 1, Dept Hepatobiliary & Pancreat Surg, Sch Med, Hangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4108
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Efficacy and safety of low-dose cyclophosphamide combined with lenvatinib, pembrolizumab and TACE for unresectable hepatocellular carcinoma:A single-center, prospective,single-arm clinical trial
    Yupeng Ren
    Yuxuan Li
    Mingbo Cao
    Yongchang Tang
    Feng Yuan
    Gaoyuan Yang
    Zhiwei He
    Zheng Shi
    Xiaorui Su
    Zhicheng Yao
    Meihai Deng
    ChineseJournalofCancerResearch, 2024, 36 (02) : 114 - 123
  • [22] TACE combined Lenvatinib plus Camrelizumab versus TACE alone in efficacy and safety for unresectable hepatocellular carcinoma: a propensity score-matching study
    Tang, Zhihong
    Bai, Tao
    Wei, Tao
    Wang, Xiaobo
    Chen, Jie
    Ye, Jiazhou
    Li, Shangqi
    Wei, Meng
    Li, Xingzhi
    Lin, Youzhi
    Tang, Juan
    Li, Lequn
    Wu, Feixiang
    BMC CANCER, 2024, 24 (01)
  • [23] Efficacy, safety, and biomarker analysis of TACE combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a real-world study
    Meng, Lingzhan
    Li, Hu
    Ji, Yingjie
    Yu, Peng
    Wang, Zizheng
    Cao, Li
    Shi, Bin
    Shao, Yanling
    Yan, Jin
    Gao, Yinjie
    Zhu, Zhenyu
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 74 (01)
  • [24] Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study
    Mao, Lili
    Fang, Meiyu
    Chen, Yu
    Wei, Xiaoting
    Cao, Jun
    Lin, Jing
    Zhang, Peng
    Chen, Ling
    Cao, Xiao
    Chen, Yujun
    Guo, Jun
    Si, Lu
    CLINICAL CANCER RESEARCH, 2022, 28 (21) : 4642 - 4648
  • [25] Efficacy and safety of tislelizumab plus lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma: a multicenter, single-arm, phase 2 trial
    Xu, Li
    Chen, Jinzhang
    Liu, Chang
    Song, Xiaoling
    Zhang, Yanqiao
    Zhao, Haitao
    Yan, Sheng
    Jia, Weidong
    Wu, Zheng
    Guo, Yabing
    Yang, Jiayin
    Gong, Wei
    Ma, Yue
    Yang, Xiaobo
    Gao, Zhenzhen
    Zhang, Nu
    Zheng, Xin
    Li, Mengyu
    Su, Dan
    Chen, Minshan
    BMC MEDICINE, 2024, 22 (01)
  • [26] PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients
    Remon, Jordi
    Girard, Nicolas
    Novello, Silvia
    de Castro, Javier
    Bigay-Game, Laurence
    Bernabe, Reyes
    Greillier, Laurent
    Mosquera, Joaquin
    Cousin, Sophie
    Juan, Oscar
    Sampayo, Miguel
    Besse, Benjamin
    CLINICAL LUNG CANCER, 2022, 23 (03) : E243 - E246
  • [27] Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial
    Xia, Yongxiang
    Tang, Weiwei
    Qian, Xiaofeng
    Li, Xiangcheng
    Cheng, Feng
    Wang, Ke
    Zhang, Feng
    Zhang, Chuanyong
    Li, Donghua
    Song, Jinhua
    Zhang, Hui
    Zhao, Jie
    Yao, Aihua
    Wu, Xiaofeng
    Wu, Chen
    Ji, Guwei
    Liu, Xisheng
    Zhu, Feipeng
    Qin, Lang
    Xiao, Xuan
    Deng, Zhenhua
    Kong, Xiangyi
    Li, Si
    Yu, Yangyang
    Xi, Wenjing
    Deng, Wanglong
    Qi, Chuang
    Liu, Hanyuan
    Pu, Liyong
    Wang, Ping
    Wang, Xuehao
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (04)
  • [28] Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II Study
    Ding, Xi
    Zhang, Wei-Jing
    You, Rui
    Zou, Xiong
    Wang, Zhi-Qiang
    Ouyang, Yan-Feng
    Peng, Lan
    Liu, You-Ping
    Duan, Chong-Yang
    Yang, Qi
    Lin, Chao
    Xie, Yu-Long
    Chen, Si-Yuan
    Liu, Yong-Long
    Gu, Chen-Mei
    Xie, Ruo-Qi
    Huang, Pei-Yu
    Hong, Ming-Huang
    Hua, Yi-Jun
    Chen, Ming-Yuan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (14) : 2571 - +
  • [29] Efficacy of Shipixiaoji Granules, Lenvatinib, and Tislelizumab in Patients with Unresectable Hepatocellular Carcinoma: Protocol for a Prospective, Single-Arm, Phase II Trial
    Zhang, Zhen
    Liang, Zicheng
    Tan, Xiaoning
    Jian, Huiying
    Gao, Wenhui
    Zeng, Puhua
    NATURAL PRODUCT COMMUNICATIONS, 2024, 19 (12)
  • [30] Transarterial chemoembolization combined with lenvatinib and camrelizumab for unresectable hepatocellular carcinoma: A prospective, single-arm, multicenter study
    Zhang, Zhibo
    Yan, Maolin
    Chen, Yufeng
    Wu, Xukun
    Yang, Lanfang
    Yin, Zhengyu
    Lu, Hao
    Zeng, Yongyi
    Zhang, Hui
    Huang, Jingyao
    Chen, Jiafei
    Wang, Liang
    Chen, Zhongwu
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345